Whilst EphA2 expression was not critical for the leukemic process, a significant level was detected on most cases of MLL-AF9 murine leukemia indicating that this protein might be a potential radiolabeled therapeutic target in the treatment of MLL-AF9 leukemias. Here, KMT2A is linked to leukemia.